394 related articles for article (PubMed ID: 35023902)
1. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
He S; Cheng Z; Xie F
Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Peng Y; Cheng Z; Xie F
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy.
Li S; Xie F
Int J Antimicrob Agents; 2019 Jan; 53(1):98-105. PubMed ID: 30626495
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
Wenzler E; Butler D; Tan X; Katsube T; Wajima T
Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
Novy E; Abdul-Aziz MH; Cheng V; Burrows F; Buscher H; Corley A; Diehl A; Gilder E; Levkovich BJ; McGuinness S; Ordonez J; Parke R; Parker S; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0120123. PubMed ID: 38063399
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic-guided gentamicin dosing in critically ill patients: a revisit of the Hartford nomogram.
He S; Cheng Z; Xie F
Int J Antimicrob Agents; 2022 Jun; 59(6):106600. PubMed ID: 35533792
[TBL] [Abstract][Full Text] [Related]
8. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy.
Xie F; Li S; Cheng Z
J Antimicrob Chemother; 2020 Jun; 75(6):1559-1566. PubMed ID: 32083673
[TBL] [Abstract][Full Text] [Related]
10. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
[TBL] [Abstract][Full Text] [Related]
11. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
[TBL] [Abstract][Full Text] [Related]
14. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
Chaijamorn W; Rungkitwattanakul D; Pattharachayakul S; Singhan W; Charoensareerat T; Srisawat N
J Crit Care; 2020 Dec; 60():285-289. PubMed ID: 32949895
[TBL] [Abstract][Full Text] [Related]
15. Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation.
Ghoneim RH; Thabit AK; Lashkar MO; Ali AS
Ital J Pediatr; 2021 Aug; 47(1):167. PubMed ID: 34362436
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of daptomycin in critically ill patients.
Soraluce A; Asín-Prieto E; Rodríguez-Gascón A; Barrasa H; Maynar J; Carcelero E; Soy D; Isla A
Int J Antimicrob Agents; 2018 Aug; 52(2):158-165. PubMed ID: 29572042
[TBL] [Abstract][Full Text] [Related]
17. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
Gatti M; Giannella M; Raschi E; Viale P; De Ponti F
J Antimicrob Chemother; 2021 Jan; 76(1):199-205. PubMed ID: 33057628
[TBL] [Abstract][Full Text] [Related]
18. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment.
Barrasa H; Soraluce A; Isla A; Martín A; Maynar J; Canut A; Sánchez-Izquierdo JA; Rodríguez-Gascón A
J Crit Care; 2019 Apr; 50():69-76. PubMed ID: 30496913
[TBL] [Abstract][Full Text] [Related]
20. Suboptimal aminoglycoside dosing in critically ill patients.
Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
